A. Bias by placement, because bias by labeling would be something to the effect of calling the liberals point of view uneducated, or giving there view some negative label, bias by omission would mean completely ignoring the other side, and not covering it at all, whereas all the other ones don't really fit, bias by placement is something to the effect of airing one side in the morning, while everyone is watching, and airing the other one after everyone is asleep, which is what is done here, which we know by the sentence "<span>liberal point of view at the end."</span>
Answer:
B) in the short run, an unexpected change in the price of an important resource can change the cost to firms.
Explanation:
The short run aggregate supply (SRAS) curve is upward sloping because as the price of goods and services increases, the quantity supplied will increase. In the short run, wages are more sticky than prices, and businesses can adjust prices more rapidly than employees can get a raise. This will result in businesses increasing their profit margins as the general level of prices increases, therefore the SRAS curve will be upward sloping.
An unexpected change in the price of a key input will shift the entire SRAS curve either to the right (price of key input decreases) or to the left (price of key input increases).
Answer:
inventory 50,000 debit
accounts payable 50,000 credit
--to record purchase of goods--
accounts payable 50,000 debit
notes payables 50,000 credit
--to record teh issued promissory note to setle the account--
cash 50,000 debit
discount on note payable 4,000 debit
notes payable 54,000 credit
--to record the discounted note--
Explanation:
a) we record the purchase as always.
b) we are trading a liability for another. We do not receive for the note.
c) we discount on the note and we are goind to declare the interest expense at maturity or year-end against this discount.
Answer: credible commitment
Explanation:
From the question, we are informed that BioGrow Pharma Inc. wanted its research partner, an R&D company, to develop a cancer vaccine but that the project required huge capital investments, and its research partner was not ready to solely face the risks involved.
Therefore, to gain its partner's confidence and to prove its involvement, BioGrow Pharma invested $100 million in the project. This investment made by BioGrow Pharma will result in a credible commitment.
